Doximity Announces Fiscal 2027 Second Quarter Financial Results
-- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, 2026. “We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin,” said Jeff Tangney, co-founder and CEO of Doximity. “More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.”
All comparisons, unless otherwise noted, are to the three months ended September 30, 2025.
• Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year.
• Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%. Non-GAAP net income of $68.3 million, versus $90.0 million, representing a margin of 39.1%, versus 53.4%.
• Adjusted EBITDA: Adjusted EBITDA of $88.9 million, versus $100.8 million, a decrease of 12% year-over-year, representing adjusted EBITDA margins of 50.9%, versus 59.8%.
• Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.18, versus $0.31, while non-GAAP diluted net income per share was $0.36, versus $0.45.
: Operating cash flow of $93.3 million, versus $93.9 million, a decrease of 1% year-over-year, and free cash flow of $91.3 million, versus $91.6 million, a decrease of less than 1% year-over-year.
Doximity is providing guidance for its fiscal third quarter ending December 31, 2026 as follows:
Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:
For more detailed financial commentary, please refer to the “Modeling Considerations” appendix in our prepared remarks. 1
Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The recorded webcast will be available on the Company’s Investor Relations page shortly after the call.
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians. With AI-powered clinical reference and search capabilities, Doximity helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements are all statements other than statements of historical fact, and specifically include statements regarding guidance and future business and financial results. These statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
September 30, 2026 March 31, 2026 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 218,614 $ 219,178 Marketable securities 494,615 529,423 Accounts receivable, net 166,113 144,783 Prepaid expenses and other current 42,200 50,880 assets Total current assets 921,542 944,264 Property and equipment, net 19,827 18,080 Deferred income tax assets 26,070 31,984 Operating lease right-of-use 6,362 7,140 assets Intangible assets, net 31,444 35,325 Goodwill 84,973 84,973 Other assets 1,552 1,921 Total assets $ 1,091,770 $ 1,123,687 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 6,304 $ 4,009 Accrued expenses and other current 35,865 42,804 liabilities Deferred revenue, current 100,227 106,050 Operating lease liabilities, 2,198 2,110 current Total current liabilities 144,594 154,973 Deferred revenue, non-current 37 400 Operating lease liabilities, 6,948 8,075 non-current Other liabilities, non-current 11,707 9,402 Total liabilities 163,286 172,850 Stockholders' Equity Preferred stock — — Common stock 178 183 Additional paid-in capital 1,068,702 1,001,688 Accumulated other comprehensive income -1,653 28 (loss) Accumulated deficit -138,743 -51,062 Total stockholders’ equity 928,484 950,837 Total liabilities and stockholders’ $ 1,091,770 $ 1,123,687 equity
(1) Costs and expenses include stock-based compensation expense as follows (in thousands):
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
• Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non- GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
• Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment, purchases of intangible assets, and internal-use software development costs.
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results. 6
Net revenue retention rate: Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business and the value we create for large customers, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin- offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.
• Quarterly unique active providers using our workflow tools: Quarterly unique active providers 1 using our Workflow Tools is a measure of our platform’s usage and adoption among healthcare providers on our platform. We calculate the number of unique active providers by counting providers who securely log in and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Ask (formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times.
1 Providers are health care professionals with clinical / prescribing roles, specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered nurse anesthetists (CRNAs), Physician assistants (PAs), Pharmacists, and Medical students. 7
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
(1) For the three and six months ended September 30, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%. 10
Full text with the tables
Exhibit 99.1
Doximity Announces Fiscal 2027 Second Quarter Financial Results
Total revenues of $174.5 million, up 4% year-over-year
Net income of $34.7 million, margin of 20%
Adjusted EBITDA of $88.9 million, margin of 51%
SAN FRANCISCO, Calif., November 5, 2026
-- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical
professionals, today announced results of its fiscal 2027 second quarter ended
September 30, 2026.
“We delivered another quarter of record engagement while investing heavily in AI
and maintaining a 51% adjusted EBITDA margin,” said Jeff Tangney, co-founder and
CEO of Doximity. “More than 190 health systems have now purchased our AI suite,
and with UpToDate and DoseCheck, we’re extending our lead in distribution and
trust.”
Fiscal 2027 Second Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended September
30, 2025.
• Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4%
year-over-year.
• Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1
million, representing a margin of 19.9%, versus 36.8%. Non-GAAP net income of
$68.3 million, versus $90.0 million, representing a margin of 39.1%, versus
53.4%.
• Adjusted EBITDA: Adjusted EBITDA of $88.9 million, versus $100.8 million, a
decrease of 12% year-over-year, representing adjusted EBITDA margins of 50.9%,
versus 59.8%.
• Diluted net income per share and non-GAAP diluted net income per share:
Diluted net income per share was $0.18, versus $0.31, while non-GAAP diluted net
income per share was $0.36, versus $0.45.
•
Operating cash flow and free cash flow
: Operating cash flow of $93.3 million, versus $93.9 million, a decrease of 1%
year-over-year, and free cash flow of $91.3 million, versus $91.6 million, a
decrease of less than 1% year-over-year.
Financial Outlook
Doximity is providing guidance for its fiscal third quarter ending December 31,
2026 as follows:
• Revenue between $195 million and $196 million.
• Adjusted EBITDA between $102.5 million and $103.5 million.
Doximity is updating guidance for its fiscal year ending March 31, 2027 as
follows:
• Revenue between $678 million and $683 million.
• Adjusted EBITDA between $317 million and $325 million.
For more detailed financial commentary, please refer to the “Modeling
Considerations” appendix in our prepared remarks.
1
Conference Call Information
Doximity posted prepared remarks on its investor relations website at
https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m.
Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To
listen to a live audio webcast, please visit the Company’s Investor Relations
page at https://investors.doximity.com. The recorded webcast will be available
on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical
professionals. The company's network members include more than 85% of U.S.
physicians. With AI-powered clinical reference and search capabilities, Doximity
helps doctors access trusted, peer-reviewed information and medical literature.
Doximity's mission is to help doctors be more productive so they can provide
better care for their patients.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities Exchange
Act. Forward-looking statements are all statements other than statements of
historical fact, and specifically include statements regarding guidance and
future business and financial results. These statements reflect our current
views about our plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans, intentions,
expectations, or strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the forward-looking
statements and will be affected by a variety of risks and factors including,
without limitation, those set forth in the section entitled “Risk Factors” in
our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and as
may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we
operate in a very competitive and rapidly changing environment. New risks and
uncertainties emerge from time to time, and it is not possible for us to predict
all risks and uncertainties that could cause actual results to differ materially
from those contained in our forward-looking statements. The forward-looking
statements made in this press release relate only to management’s beliefs and
assumptions as of this date. We assume no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.
Investor Relations Contact:
Perry Gold
[email protected]
Media Contact:
Richard George
[email protected]
2
DOXIMITY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
September 30, 2026 March 31, 2026
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash equivalents $ 218,614 $ 219,178
Marketable securities 494,615 529,423
Accounts receivable, net 166,113 144,783
Prepaid expenses and other
current 42,200 50,880
assets
Total current assets 921,542 944,264
Property and equipment, net 19,827 18,080
Deferred income tax assets 26,070 31,984
Operating lease right-of-use 6,362 7,140
assets
Intangible assets, net 31,444 35,325
Goodwill 84,973 84,973
Other assets 1,552 1,921
Total assets $ 1,091,770 $ 1,123,687
Liabilities and Stockholders’
Equity
Current liabilities:
Accounts payable $ 6,304 $ 4,009
Accrued expenses and other
current 35,865 42,804
liabilities
Deferred revenue, current 100,227 106,050
Operating lease liabilities, 2,198 2,110
current
Total current liabilities 144,594 154,973
Deferred revenue, non-current 37 400
Operating lease liabilities, 6,948 8,075
non-current
Other liabilities, non-current 11,707 9,402
Total liabilities 163,286 172,850
Stockholders' Equity
Preferred stock — —
Common stock 178 183
Additional paid-in capital 1,068,702 1,001,688
Accumulated other
comprehensive income -1,653 28
(loss)
Accumulated deficit -138,743 -51,062
Total stockholders’ equity 928,484 950,837
Total liabilities and
stockholders’ $ 1,091,770 $ 1,123,687
equity
3
DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Six
Months Months
Ended Ended
Septemb… Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Revenue $ 174,537 $ 168,525 $ 331,155 $ 314,438
Cost of 25,346 16,425 49,038 32,218
revenu…
Gross 149,191 152,100 282,117 282,220
profit
Operat…
expens…
Resear…
and 41,961 30,202 80,439 57,001
develo…
Sales
and 46,892 39,168 91,941 75,533
market…
General
and 16,416 19,049 32,172 31,488
admini…
Total
operat… 105,269 88,419 204,552 164,022
expens…
Income
from 43,922 63,681 77,565 118,198
operat…
Other
income, 6,405 9,258 13,124 18,888
net
Income
before 50,327 72,939 90,689 137,086
income
taxes
Provis…
for 15,597 10,880 31,645 21,707
income
taxes
Net $ 34,730 $ 62,059 $ 59,044 $ 115,379
income
Net
income
per
share
attrib…
to
Class A
and
Class B
common
stockh…
Basic $ 0.19 $ 0.33 $ 0.33 $ 0.61
Diluted $ 0.18 $ 0.31 $ 0.31 $ 0.57
Weight…
shares
used in
comput…
net
income
per
share
attrib…
to
Class A
and
Class B
common
stockh…
Basic 178,674 187,705 180,611 187,844
Diluted 187,804 200,745 189,475 200,952
(1) Costs and expenses include stock-based compensation expense as follows (in
thousands):
Three Six
Months Months
Ended Ended
Septemb… September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Cost of $ 3,036 $ 2,844 $ 6,228 $ 5,824
revenue
Resear…
and 16,028 9,862 31,587 16,511
develo…
Sales
and 12,696 10,508 25,121 18,218
market…
General
and 8,805 6,260 14,381 10,786
admini…
Total
stock-… $ 40,565 $ 29,474 $ 77,317 $ 51,339
compen…
expense
4
DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Six
Cash Months Months
flows Ended Ended
from Septe… Septem…
oper… 30, 30,
acti… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 34,730 $ 62,059 $ 59,044 $ 115,379
inco…
Adju…
to
reco…
net
inco…
to
net
cash
prov…
by
oper…
acti…
Depr…
and 4,353 3,469 8,640 6,263
amor…
Stoc…
comp…
net 40,565 29,474 77,317 51,339
of
amou…
capi…
Non-…
lease 391 454 778 904
expe…
Accr…
of
disc…
on -358 -2,199 -925 -4,687
mark…
secu…
net
Amor…
of
defe… 3,858 2,876 8,158 6,772
cont…
costs
Other 358 294 20 -114
Chan…
in
oper…
asse…
and
liab…
Acco… 11,366 12,396 -21,9… -985
rece…
Prep…
expe…
and 5,259 7,685 14,384 3,451
other
asse…
Defe…
cont… -2,577 -2,584 -5,219 -4,549
costs
Acco…
paya…
accr…
expe… 4,701 -2,168 2,268 -2,333
and
other
liab…
Defe… -8,834 -17,2… -6,186 -14,268
reve…
Oper…
lease -527 -571 -1,039 -1,127
liab…
Net
cash
prov… 93,285 93,944 135,2… 156,045
by
oper…
acti…
Cash
flows
from
inve…
acti…
Cash
paid
for
acqu… — -26,5… — -26,528
net
of
cash
acqu…
Purc…
of
prop… — — -62 —
and
equi…
Inte…
soft… -1,953 -2,369 -4,275 -4,335
deve…
costs
Purc…
of -168,4… -128,… -183,… -268,2…
mark…
secu…
Matu…
of 86,396 125,4… 212,4… 270,031
mark…
secu…
Sales
of — — 4,049 —
mark…
secu…
Net
cash
prov…
by -84,033 -31,7… 28,957 -29,032
(used
in)
inve…
acti…
Cash
flows
from
fina…
acti…
Proc…
from
issu…
of
comm…
stock
upon
exer… 908 2,398 3,988 4,796
of
stock
opti…
and
comm…
stock
warr…
Proc…
from
issu…
of
comm…
stock
in 1,288 1,816 1,288 1,816
conn…
with
the
empl…
stock
purc…
plan
Taxes
paid
rela…
to
net -9,948 -12,5… -16,9… -24,493
share
sett…
of
equi…
awar…
Repu…
of -54,198 -21,8… -145,… -144,2…
comm…
stock
Paym…
of
cont…
cons… — — -5,024 -5,249
rela…
to a
busi…
comb…
Paym…
of
exci…
taxes -2,292 — -2,292 —
on
share
repu…
Net
cash
used -64,242 -30,2… -164,… -167,3…
in
fina…
acti…
Net
incr…
(dec…
in -54,990 31,988 -564 -40,365
cash
and
cash
equi…
Cash
and
cash
equi… 273,604 137,2… 219,1… 209,614
begi…
of
peri…
Cash
and
cash
equi… $ 218,614 $ 169,2… $ 218,6… $ 169,249
end
of
peri…
Supp…
disc…
of
cash
flow
info…
Cash
paid
for
taxe… $ 10,126 $ 14,369 $ 14,116 $ 19,347
net
of
refu…
5
Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, which are
prepared and presented in accordance with accounting principles generally
accepted in the United States (“GAAP”), the Company uses the following non-GAAP
measures of financial performance:
• Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-
GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net
income per common share: We exclude the effect of acquisition and other related
expenses, stock-based compensation expense, amortization of acquired intangible
assets, legal fees associated with certain non-ordinary course legal matters
including the shareholder class action litigation, and change in fair value of
contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP
gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net
income margin are further adjusted for estimated income tax on such adjustments.
We calculate income taxes on the adjustments by applying an estimated annual
effective tax rate to the adjustments. Non-GAAP basic and diluted net income per
common share is non-GAAP net income attributable to common stockholders divided
by the weighted average number of shares. For both basic and diluted non-GAAP
net income per share, the weighted average shares we use in computing non-GAAP
net income per share is equal to our GAAP weighted average shares. Non-GAAP
gross margin represents non-GAAP gross profit as a percentage of revenue and
non-GAAP net income margin represents non-GAAP net income as a percentage of
revenue.
•
Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net
income before interest, income taxes, depreciation, and amortization, and as
further adjusted for acquisition and other related expenses, stock-based
compensation expense, legal fees associated with certain non-ordinary course
legal matters including the shareholder class action litigation, change in fair
value of contingent earn-out consideration liability, and other income, net. Net
income margin represents net income as a percentage of revenue and adjusted
EBITDA margin represents adjusted EBITDA as a percentage of revenue.
• Free cash flow: We calculate free cash flow as cash flow from operating
activities less purchases of property and equipment, purchases of intangible
assets, and internal-use software development costs.
We use these non-GAAP financial measures internally for financial and
operational decision-making purposes and as a means to evaluate period-to-period
comparisons. Non-GAAP financial measures are not meant to be considered in
isolation or as a substitute for comparable GAAP financial measures and should
be read only in conjunction with our condensed consolidated financial statements
prepared in accordance with GAAP. Our presentation of non-GAAP financial
measures may not be comparable to similar measures used by other companies. We
encourage investors to carefully consider our results under GAAP, as well as our
supplemental non-GAAP information and the reconciliation between these
presentations, to more fully understand our business. Please see the tables
included at the end of this release for the reconciliation of GAAP to non-GAAP
results.
6
Key Business Metrics
•
Net revenue retention rate: Our net revenue retention rate compares our
subscription revenue from the same set of customers across comparable periods,
and reflects customer renewals, expansion, contraction, and churn. Net revenue
retention rate is calculated by taking the trailing 12-month (“TTM”)
subscription-based revenue from our customers that had revenue in the prior TTM
period and dividing that by the total subscription-based revenue for the prior
TTM period. For the purposes of this calculation, subscription revenue excludes
subscriptions for individuals and small practices and other non-recurring items.
Our net revenue retention rate is directly tied to our revenue growth rate and
thus fluctuates as that growth rate fluctuates.
•
Customers with trailing 12-month subscription revenue greater than $500,000: The
number of customers with TTM subscription revenue greater than $500,000 is a key
indicator of the scale of our business and the value we create for large
customers, and is calculated by counting the number of customers that
contributed more than $500,000 in subscription revenue in the TTM period. Our
customer count is subject to adjustments for acquisitions, consolidations, spin-
offs, and other market activity, and we present our total customer count for
historical periods reflecting these adjustments.
• Quarterly unique active providers using our workflow tools: Quarterly unique
active providers 1 using our Workflow Tools is a measure of our platform’s usage
and adoption among healthcare providers on our platform. We calculate the number
of unique active providers by counting providers who securely log in and use any
of the following workflow functions on our technology platform during the
quarter: placing phone calls or video calls lasting more than 10 seconds,
sending voicemails, or sending secure text messages using our Dialer
communications tools; sending or receiving faxes; submitting a prompt on Ask
(formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and
writing assistant; conducting research on prescription drugs; reviewing AI
responses for our PeerCheck feature; scheduling via our on-call scheduling tool,
Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a
patient visit. Each provider is counted once per quarter, even if they use
multiple tools or use them many times.
1 Providers are health care professionals with clinical / prescribing roles,
specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered
nurse anesthetists (CRNAs), Physician assistants (PAs), Pharmacists, and Medical
students.
7
Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in
the calculation of non-GAAP metrics for the periods shown below:
Three
Mont…
Ended
Sept…
30,
2026 Six
(una… Mon…
(in End…
thou… Sep…
exce… 30,
perc… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 34,7… $ 62,0… $ 59,0… $ 115…
inc…
Adj…
to
exc…
the
fol…
Acq…
and
oth… — 1,188 — 1,6…
rel…
exp…
Sto… 40,5… 29,4… 77,3… 51,…
com…
Dep…
and 4,353 3,469 8,640 6,2…
amo…
Pro…
for 15,5… 10,8… 31,6… 21,…
inc…
tax…
Cha…
in
fair
val…
of — 91 90 259
con…
ear…
con…
lia…
Leg… 25 2,927 25 2,9…
exp…
Oth…
inc… -6,4… -9,2… -13,… -18…
net
Adj… $ 88,8… $ 100,… $ 163,… $ 180…
EBI…
Rev… $ 174,… $ 168,… $ 331,… $ 314…
Net
inc… 20 % 37 % 18 % 37 %
mar…
Adj…
EBI… 51 % 60 % 49 % 57 %
mar…
Three
Months
Ended
Septem… Six
30, Months
2026 Ended
(unaud… Septe…
(in 30,
thousa… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
prov… $ 93,285 $ 93,944 $ 135,272 $ 156,0…
by
oper…
acti…
Purc…
of
prop… — — -62 —
and
equi…
Inte…
soft… -1,953 -2,369 -4,275 -4,335
deve…
costs
Free
cash $ 91,332 $ 91,575 $ 130,935 $ 151,7…
flow
Other
cash
flow
comp…
Net
cash
prov…
by $ -84,0… $ -31,711 $ 28,957 $ -29,0…
(used
in)
inve…
acti…
Net
cash
used $ -64,2… $ -30,245 $ -164,7… $ -167,…
in
fina…
acti…
8
Three
Mont…
Ended
Sept…
30,
2026
(una…
(in
thou…
exce… Six
per Mon…
share End…
data Sep…
and 30,
perc… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
cost $ 25,3… $ 16,4… $ 49,0… $ 32,…
of
rev…
Adj…
to
exc…
the
fol…
Sto… -3,0… -2,8… -6,2… -5,…
com…
Amo…
of -935 — -1,8… —
acq…
int…
Non…
cost $ 21,3… $ 13,5… $ 40,9… $ 26,…
of
rev…
GAAP
gro… $ 149,… $ 152,… $ 282,… $ 282…
pro…
Adj…
to
exc…
the
fol…
Sto… 3,036 2,844 6,228 5,8…
com…
Amo…
of 935 — 1,870 —
acq…
int…
Non…
gro… $ 153,… $ 154,… $ 290,… $ 288…
pro…
GAAP
gro… 85.5 % 90.3 % 85.2 % 89.8 %
mar…
Non…
gro… 87.8 % 91.9 % 87.6 % 91.6 %
mar…
GAAP
res…
and $ 41,9… $ 30,2… $ 80,4… $ 57,…
dev…
exp…
Adj…
to
exc…
the
fol…
Sto… -16,… -9,8… -31,… -16…
com…
Amo…
of — -623 — -623
acq…
int…
Non…
res…
and $ 25,9… $ 19,7… $ 48,8… $ 39,…
dev…
exp…
GAAP
sal…
and $ 46,8… $ 39,1… $ 91,9… $ 75,…
mar…
exp…
Adj…
to
exc…
the
fol…
Sto… -12,… -10,… -25,… -18…
com…
Amo…
of -1,0… -1,0… -2,0… -2,…
acq…
int…
Cha…
in
fair
val…
of — -91 -90 -259
con…
ear…
con…
lia…
Non…
sal…
and $ 33,1… $ 27,5… $ 64,7… $ 55,…
mar…
exp…
GAAP
gen…
and $ 16,4… $ 19,0… $ 32,1… $ 31,…
adm…
exp…
Adj…
to
exc…
the
fol…
Acq…
and
oth… — -1,1… — -1,…
rel…
exp…
Sto… -8,8… -6,2… -14,… -10…
com…
Leg… -25 -2,9… -25 -2,…
exp…
Non…
gen…
and $ 7,586 $ 8,674 $ 17,7… $ 16,…
adm…
exp…
GAAP
ope… $ 105,… $ 88,4… $ 204,… $ 164…
exp…
Adj…
to
exc…
the
fol…
Acq…
and
oth… — -1,1… — -1,…
rel…
exp…
Sto… -37,… -26,… -71,… -45…
com…
Amo…
of -1,0… -1,6… -2,0… -2,…
acq…
int…
Cha…
in
fair
val…
of — -91 -90 -259
con…
ear…
con…
lia…
Leg… -25 -2,9… -25 -2,…
exp…
Non…
ope… $ 66,7… $ 55,9… $ 131,… $ 111…
exp…
9
Three
Mont…
Ended
Sept…
30,
2026
(una…
(in
thou…
exce… Six
per Mon…
share End…
data Sep…
and 30,
perc… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
ope… $ 43,9… $ 63,6… $ 77,5… $ 118…
inc…
Adj…
to
exc…
the
fol…
Acq…
and
oth… — 1,188 — 1,6…
rel…
exp…
Sto… 40,5… 29,4… 77,3… 51,…
com…
Amo…
of 1,940 1,625 3,881 2,6…
acq…
int…
Cha…
in
fair
val…
of — 91 90 259
con…
ear…
con…
lia…
Leg… 25 2,927 25 2,9…
exp…
Non…
ope… $ 86,4… $ 98,9… $ 158,… $ 176…
inc…
GAAP
net $ 34,7… $ 62,0… $ 59,0… $ 115…
inc…
Adj…
to
exc…
the
fol…
Acq…
and
oth… — 1,188 — 1,6…
rel…
exp…
Sto… 40,5… 29,4… 77,3… 51,…
com…
Amo…
of 1,940 1,625 3,881 2,6…
acq…
int…
Cha…
in
fair
val…
of — 91 90 259
con…
ear…
con…
lia…
Leg… 25 2,927 25 2,9…
exp…
Inc…
tax
eff… -8,9… -7,4… -17,… -12…
of
non…
adj…
Non…
net $ 68,3… $ 89,9… $ 123,… $ 161…
inc…
Non…
net 39.1 % 53.4 % 37.2 % 51.5 %
inc…
mar…
Wei…
sha…
used
in
com…
net
inc…
per
sha…
att…
to
Cla…
A
and
Cla…
B
com…
sto…
Bas… 178,… 187,… 180,… 187…
Dil… 187,… 200,… 189,… 200…
Non…
net
inc…
per
sha…
att…
to
Cla…
A
and
Cla…
B
sto…
Bas… $ 0.38 $ 0.48 $ 0.68 $ 0.86
Dil… $ 0.36 $ 0.45 $ 0.65 $ 0.81
(1) For the three and six months ended September 30, 2026 and 2025, management
used an estimated annual effective non-GAAP tax rate of 21.0%.
10